Background: IκBζ plays a key role in psoriasis by mediating IL-17A–driven effects, but the molecular mechanism by which IL-17A regulates IκBζ expression is not clarified. Objective: We sought to explore the molecular transformation in patients with psoriasis during anti-IL-17A (secukinumab) treatment with a focus on IκBζ. Methods: The study was an open-label, single-arm, single-center secukinumab treatment study that included 14 patients with plaque psoriasis. Skin biopsy specimens and blood samples were collected on days 0, 4, 14, 42, and 84 and processed for microarray gene expression analysis. Furthermore, in vitro experiments with human keratinocytes and synovial fibroblasts were conducted. Results: Secukinumab improved clinical scor...
[[abstract]]Psoriasis, a complex inflammatory autoimmune skin disorder that affects 2-3% of the glob...
Psoriasis is a chronic inflammatory skin disease affecting about 1–3 % of the general population. Mo...
Psoriasis is a T-cell mediated disease that involves IL-23/Th17 and IL-12/Th1 axes. Ustekinumab, a f...
Background : In recent years, use of biological therapy in psoriasis has increased as a result of ad...
BACKGROUND: Ustekinumab is a fully human anti-p40 monoclonal antibody which neutralizes interleukin ...
BACKGROUND Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluat...
BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluat...
Psoriasis is a chronic inflammatory skin disease affecting about 1–3% of the general population. Mod...
Background: Psoriasis is an immunologic-mediated disease affected by genetic factors that may affect...
Introduction: Secukinumab is a fully human monoclonal antibody that selectively neutralizes IL-17A, ...
<div><p>Psoriasis is a chronic cutaneous inflammatory disease. The immunopathogenesis is a complex i...
The pro-inflammatory cytokine interleukin (IL)-17A plays a pivotal role in psoriasis pathogenesis. S...
Psoriasis is a chronic cutaneous inflammatory disease. The immunopathogenesis is a complex interplay...
Durable psoriasis improvement has been reported in a subset of psoriasis patients after treatment wi...
BACKGROUND: In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and sy...
[[abstract]]Psoriasis, a complex inflammatory autoimmune skin disorder that affects 2-3% of the glob...
Psoriasis is a chronic inflammatory skin disease affecting about 1–3 % of the general population. Mo...
Psoriasis is a T-cell mediated disease that involves IL-23/Th17 and IL-12/Th1 axes. Ustekinumab, a f...
Background : In recent years, use of biological therapy in psoriasis has increased as a result of ad...
BACKGROUND: Ustekinumab is a fully human anti-p40 monoclonal antibody which neutralizes interleukin ...
BACKGROUND Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluat...
BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluat...
Psoriasis is a chronic inflammatory skin disease affecting about 1–3% of the general population. Mod...
Background: Psoriasis is an immunologic-mediated disease affected by genetic factors that may affect...
Introduction: Secukinumab is a fully human monoclonal antibody that selectively neutralizes IL-17A, ...
<div><p>Psoriasis is a chronic cutaneous inflammatory disease. The immunopathogenesis is a complex i...
The pro-inflammatory cytokine interleukin (IL)-17A plays a pivotal role in psoriasis pathogenesis. S...
Psoriasis is a chronic cutaneous inflammatory disease. The immunopathogenesis is a complex interplay...
Durable psoriasis improvement has been reported in a subset of psoriasis patients after treatment wi...
BACKGROUND: In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and sy...
[[abstract]]Psoriasis, a complex inflammatory autoimmune skin disorder that affects 2-3% of the glob...
Psoriasis is a chronic inflammatory skin disease affecting about 1–3 % of the general population. Mo...
Psoriasis is a T-cell mediated disease that involves IL-23/Th17 and IL-12/Th1 axes. Ustekinumab, a f...